: Evaluating the Safety and Tolerability of PLN-74809, a Dual-Selective Inhibitor of Integrins αvβ6 and αvβ1

Time: 9:00 am
day: Day Two


  • No treatment-related effects in chronic GLP toxicology studies; NOAEL set at the highest dose tested
  • PLN-74809 has been administered to over 450 study participants to date and shown to be well tolerated
  • Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification and proceed to evaluate dosing at 320mg